{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T21:31:00Z","timestamp":1757539860382},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,23]]},"DOI":"10.7759\/cureus.67597","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:46:53Z","timestamp":1724424413000},"source":"Crossref","is-referenced-by-count":1,"title":["Osimertinib-Induced Myositis in a Patient With Metastatic Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation"],"prefix":"10.7759","author":[{"given":"Aatma","family":"Ram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun T","family":"Siu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abir","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranju","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel RL","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020, 70:7-30. 10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti AK","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021, 7:1824-32. 10.1001\/jamaoncol.2021.4932","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch TJ","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, et al.. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350:2129-39. 10.1056\/NEJMoa040938","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao W","year":"2004","unstructured":"Pao W, Miller V, Zakowski M, et al.. EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004, 101:13306-11. 10.1073\/pnas.0405220101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref5","article-title":"The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia","volume":"19","author":"Arteaga CL","year":"2001","unstructured":"Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 2001, 19:32S-40S.","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100260","article-title":"Life-threatening myositis in a patient with EGFR-mutated NSCLC on osimertinib: case report","volume":"3","author":"Crowley F","year":"2022","unstructured":"Crowley F, Fitzgerald BG, Bhardwaj AS, Siraj I, Smith C. Life-threatening myositis in a patient with EGFR-mutated NSCLC on osimertinib: case report. JTO Clin Res Rep. 2022, 3:100260. 10.1016\/j.jtocrr.2021.100260","journal-title":"JTO Clin Res Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100254","article-title":"Myositis-a common but underreported adverse effect of osimertinib: case series and review of the literature","volume":"25","author":"Parafianowicz P","year":"2020","unstructured":"Parafianowicz P, Krishan R, Beutler BD, Islam RX, Singh T. Myositis-a common but underreported adverse effect of osimertinib: case series and review of the literature. Cancer Treat Res Commun. 2020, 25:100254. 10.1016\/j.ctarc.2020.100254","journal-title":"Cancer Treat Res Commun"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.03.014","article-title":"Myositis in a patient with advanced lung cancer treated with osimertinib","volume":"13","author":"Fujioka S","year":"2018","unstructured":"Fujioka S, Kitajima T, Itotani R. Myositis in a patient with advanced lung cancer treated with osimertinib. J Thorac Oncol. 2018, 13:e137-9. 10.1016\/j.jtho.2018.03.014","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211042271","article-title":"Elevated serum creatine kinase levels due to osimertinib: a case report and review of the literature","volume":"28","author":"Sugimoto H","year":"2022","unstructured":"Sugimoto H, Matsumoto S, Tsuji Y, Sugimoto K. Elevated serum creatine kinase levels due to osimertinib: a case report and review of the literature. J Oncol Pharm Pract. 2022, 28:489-94. 10.1177\/10781552211042271","journal-title":"J Oncol Pharm Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-916","article-title":"Rhabdomyolysis in a patient with advanced lung cancer treated with osimertinib: a case report","volume":"12","author":"Li Y","year":"2023","unstructured":"Li Y, Liu Y, Zhao Z, Zhang Y. Rhabdomyolysis in a patient with advanced lung cancer treated with osimertinib: a case report. Transl Lung Cancer Res. 2023, 12:629-36. 10.21037\/tlcr-22-916","journal-title":"Transl Lung Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2020.06.021","article-title":"Osimertinib for the treatment of EGFR mutation-positive lung adenocarcinoma complicated with dermatomyositis","volume":"56","author":"Yamasaki M","year":"2020","unstructured":"Yamasaki M, Matsumoto N, Nakano S, et al.. Osimertinib for the treatment of EGFR mutation-positive lung adenocarcinoma complicated with dermatomyositis. Arch Bronconeumol. 2020, 56:822-3. 10.1016\/j.arbres.2020.06.021","journal-title":"Arch Bronconeumol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria JC","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al.. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018, 378:113-25. 10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu YL","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, et al.. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020, 383:1711-23. 10.1056\/NEJMoa2027071","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu S","year":"2024","unstructured":"Lu S, Kato T, Dong X, et al.. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024, 391:585-97. 10.1056\/NEJMoa2402614","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.23-00007","article-title":"Gefitinib-induced myositis: a novel case report","volume":"143","author":"Sakamoto T","year":"2023","unstructured":"Sakamoto T, Saito Y, Takekuma Y, Kikuchi E, Sugawara M. Gefitinib-induced myositis: a novel case report. Yakugaku Zasshi. 2023, 143:617-20. 10.1248\/yakushi.23-00007","journal-title":"Yakugaku Zasshi"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S194870","article-title":"Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer","volume":"12","author":"Xu ZY","year":"2019","unstructured":"Xu ZY, Li JL. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. OncoTargets Ther. 2019, 12:5467-84. 10.2147\/OTT.S194870","journal-title":"OncoTargets Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/271024-osimertinib-induced-myositis-in-a-patient-with-metastatic-non-small-cell-lung-cancer-with-epidermal-growth-factor-receptor-mutation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:46:56Z","timestamp":1724424416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/271024-osimertinib-induced-myositis-in-a-patient-with-metastatic-non-small-cell-lung-cancer-with-epidermal-growth-factor-receptor-mutation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.67597","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,23]]}}}